IRIS
Fiorino, Gionata
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.915
EU - Europa 1.453
AS - Asia 370
AF - Africa 249
OC - Oceania 14
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.832
FI - Finlandia 404
IE - Irlanda 265
NG - Nigeria 224
CN - Cina 177
FR - Francia 141
DE - Germania 139
IT - Italia 111
SE - Svezia 96
NL - Olanda 92
GB - Regno Unito 89
CA - Canada 76
TR - Turchia 41
IL - Israele 38
IN - India 38
BE - Belgio 29
RU - Federazione Russa 21
SG - Singapore 20
ES - Italia 19
IR - Iran 12
UA - Ucraina 12
AU - Australia 11
DZ - Algeria 11
EG - Egitto 11
JP - Giappone 11
CL - Cile 7
HK - Hong Kong 7
RO - Romania 7
IQ - Iraq 6
MX - Messico 5
PT - Portogallo 5
VN - Vietnam 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
BR - Brasile 3
EU - Europa 3
NZ - Nuova Zelanda 3
QA - Qatar 3
AT - Austria 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BO - Bolivia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
KZ - Kazakistan 2
MD - Moldavia 2
PK - Pakistan 2
BD - Bangladesh 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
KR - Corea 1
MT - Malta 1
MY - Malesia 1
PH - Filippine 1
PL - Polonia 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.020
Salva come PNG Salva come JPEG
Città #
Wilmington 1.555
Chandler 1.248
San Mateo 589
Ann Arbor 437
Helsinki 404
Leawood 287
Lawrence 273
Princeton 273
Dublin 260
Benin City 223
Boardman 183
Ashburn 169
Woodbridge 152
Fairfield 151
Shanghai 149
Paris 141
New York 140
Amsterdam 86
Toronto 68
London 54
Norwalk 47
Kocaeli 40
Milan 39
Seattle 31
Brussels 28
Monmouth Junction 28
San Diego 28
Phoenix 26
Redwood City 26
Pune 17
Abbiategrasso 16
Cambridge 16
Singapore 16
Beijing 11
Houston 9
Collegeville 8
Moscow 8
Redmond 8
Warrington 8
Bury 7
Des Moines 7
Duncan 7
Falkenstein 7
Sacramento 7
Baghdad 6
Cairo 6
Gunzenhausen 6
Kemerovo 6
Valencia 6
Kikunodai 5
St Louis 5
Andover 4
Clearwater 4
Delhi 4
Henderson 4
Hong Kong 4
Lisbon 4
San Pedro 4
Tappahannock 4
Washington 4
Zhengzhou 4
Asyut 3
Brisbane 3
Cupertino 3
Doha 3
Glasgow 3
Hanoi 3
Hanover 3
Heerenveen 3
Hyderabad 3
Las Vegas 3
Oran 3
Osaka 3
Padova 3
Raleigh 3
Seville 3
Sydney 3
Zanjan 3
Acate 2
Alcalá de Henares 2
Algiers 2
Almaty 2
Auckland 2
Augusta 2
Banja Luka 2
Bantry 2
Cagliari 2
Chisinau 2
Groningen 2
Ho Chi Minh City 2
Hull 2
La Paz 2
Leeds 2
Limerick 2
Linköping 2
Manchester 2
Miami 2
Montichiari 2
Mumbai 2
Napoli 2
Totale 7.462
Salva come PNG Salva come JPEG
Nome #
ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease Part 1. Initial diagnosis, monitoring of known IBD, detections of complications 159
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 82
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (R) (Cortiment (R)(MMX (R))) for active, mild-to-moderate ulcerative colitis 71
Adalimumab in ulcerative colitis: hypes and hopes 67
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 64
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 60
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 56
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 55
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 55
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 54
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 54
JAK inhibitors: Novel developments in management of ulcerative colitis 54
Accuracy of a New Fujiifilm Blue Light Prototype in Predicting the Histology of Subcentimetric Polyps 54
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 53
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 53
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 53
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 53
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 53
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 53
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 52
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 52
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 52
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 52
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 51
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 51
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 51
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 51
Emerging therapeutic targets and strategies in Crohn's disease 50
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 50
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target 50
Risk of postoperative recurrence and postoperative management of Crohn's disease 49
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 49
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile 49
Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation 49
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 48
Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside 48
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 48
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 48
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis 48
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? 47
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 47
Are Surgical Rates Decreasing in the Biological Era In IBD? 47
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target 46
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 46
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease 46
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 45
Familial aggregation in inflammatory bowel disease: Is it genes or environment? 45
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 45
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 44
Perception of Reproductive Health in Women with Inflammatory Bowel Disease (vol 10, pg 886, 2016) 44
A HEALTH TECHNOLOGY-RELATED COST DESCRIPTION CONCERNING ITALIAN IBD CENTRES DEALING WITH CROHN'S DISEASE: RESULTS FROM SOLE STUDY 44
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy 43
Adalimumab for the treatment of pediatric Crohn's disease 43
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 43
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 43
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 43
Effect of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's disease: a tertiary centre real-life experience 43
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 42
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 42
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 42
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? 42
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling 42
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease 42
Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD 42
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX (R) for mild-to-moderate ulcerative colitis 42
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? 41
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target 41
Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis 41
Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease 41
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update 41
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 41
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study 41
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials 40
Commentary: antibodies reacting with the infliximab Fab portion - something new? 40
Clinical utility of the Lemann index and Rutgeerts score to predict postoperative course of Crohn's disease: a retrospective single-center cohort study. 40
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation 40
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 40
Novel therapeutic targets for inflammatory bowel disease 40
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 40
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group 40
MRI in Crohn's disease : current and future clinical applications 39
Early intervention in Crohn's disease: towards disease modification trials 39
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 39
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease 39
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 39
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 38
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study 38
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease 38
Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition 38
Vedolizumab for the treatment of Crohn's disease 38
The safety of biological pharmacotherapy for the treatment of ulcerative colitis 38
VAGUS NERVE STIMULATION REDUCES DISEASE ACTIVITY AND MODULATES SERUM AND AUTONOMIC BIOMARKERS IN BIOLOGICREFRACTORY CROHN'S DISEASE 38
'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review 38
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis 38
Calcium supplementation for the prevention of colorectal adenomas: a systematic review and meta-analysis of randomized controlled trials 38
Clinical Utility of the LeMann Index and Rutgeerts Score to Predict Postoperative Course of Crohn's Disease: A Retrospective Single-Center Cohort Study 38
Cross-Sectional Imaging Modalities in Crohn's Disease 37
Psychological Functioning of Patients With Inflammatory Bowel Disease 37
Integrins and adhesion molecules as targets to treat inflammatory bowel disease 37
Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis 37
Totale 4.709
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.927
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.927
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020112 0 0 0 0 0 0 0 0 0 0 0 112
2020/20212.874 11 28 19 25 21 898 381 197 614 337 15 328
2021/20221.516 99 15 65 306 12 8 64 197 152 203 312 83
2022/20233.347 617 152 389 351 205 283 16 255 541 325 169 44
2023/20241.423 201 152 384 93 56 257 103 118 34 25 0 0
Totale 9.272